# IDG-16177 for the Evaluation of Its Safety and Pharmacokinetics

> **NCT04982705** · PHASE1 · UNKNOWN · sponsor: **IlDong Pharmaceutical Co Ltd** · enrollment: 94 (estimated)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** [Part 1.1] IDG-16177
- **DRUG:** [Part 1.1] Placebo of IDG-16177
- **DRUG:** [Part 2] Sitagliptin
- **DRUG:** [Part1.2] IDG-16177
- **DRUG:** [Part 2] IDG-16177
- **DRUG:** [Part 1.2] Placebo of IDG-16177
- **DRUG:** [Part 2] Placebo of IDG-16177

## Key facts

- **NCT ID:** NCT04982705
- **Lead sponsor:** IlDong Pharmaceutical Co Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-07-07
- **Primary completion:** 2022-11-09
- **Final completion:** 2022-12-30
- **Target enrollment:** 94 (ESTIMATED)
- **Last updated:** 2022-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04982705

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04982705, "IDG-16177 for the Evaluation of Its Safety and Pharmacokinetics". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT04982705. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*